Search
Group A Streptococcal (GAS) pharyngitis is an important precursor infection to severe complications including rheumatic fever and invasive GAS. Rapid molecular point of care testing (POCT) for GAS infection has advantages over traditional microbiological culture, especially in settings with limited or absent laboratory infrastructure and where GAS complications predominate.
The prevalence of impetigo and pharyngitis - which are both superficial group A streptococcus (GAS) infections that precede acute rheumatic fever - is poorly defined. Guidelines recommend the early diagnosis of both infections to prevent ARF; however, screening to enable the concurrent detection of these infections in high-risk populations has rarely been performed.
Group A Streptococcus (GAS) is a Gram-positive bacterial pathogen that causes an array of infectious diseases in humans. Accumulating clinical evidence suggests that proinflammatory interleukin (IL)-1beta signaling plays an important role in GAS disease progression.
An optimized, rapid method for creating markerless isogenic mutations that combines Gibson assembly cloning with a new temperature-sensitive plasmid, pLZts
Currently there are no diagnostic tests for ARF, and no treatments targeting immune responses to improve disease outcomes.
ARC is a global network of collaborators committed to reducing the burden of RHD in our lifetime.
A vaccine that prevents the initial attachment of Strep A to the tonsils would reduce the incidence of Strep throat and severe diseases that result.
Strep A causes over 775 million infections each year world-wide, including over 615 million cases of tonsil infection (Strep throat).
The skin is home to an array of bacteria, fungi and viruses, which together make up the skin microbiome. We explore how the skin microbiome can contribute to healthy skin.
Investigating what risk does underlying trimethoprim resistance pose for the development of cotrimoxazole-resistant skin infections.